Real-World Effectiveness of Tafamidis 80 mg or 61 mg on Neurologic Disease Progression in Patients With Mixed-Phenotype Hereditary Transthyretin Amyloid Cardiomyopathy
Conditions: Hereditary Transthyretin Amyloidosis (ATTRv) Cardiomyopathy (CM), Mixed Phenotype
Sponsor: Pfizer



Document Approval Record
Document Name:
	
      

	 !

Document Title:
	
      

	 !

Signed By:
Date(GMT)
Signing Capacity
	$ !$
 
%&&%	
' ((
PPD